{"id":54394,"date":"2026-04-02T23:05:30","date_gmt":"2026-04-02T23:05:30","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/54394\/"},"modified":"2026-04-02T23:05:30","modified_gmt":"2026-04-02T23:05:30","slug":"lillys-fda-approved-oral-weight-loss-pill-puts-novo-nordisks-wegovy-franchise-under-fresh-pressure","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/54394\/","title":{"rendered":"Lilly’s FDA-approved oral weight-loss pill puts Novo Nordisk’s Wegovy franchise under fresh pressure"},"content":{"rendered":"

\"GLP-1 GLP-1 wars: Lilly’s FDA-approved oral weight-loss pill puts Novo Nordisk’s Wegovy franchise under fresh pressure Proactive uses images sourced from Shutterstock <\/p>\n

Foundayo launches on April 6 at the same price as Novo’s pill, threatening to reshape the $50 billion obesity drug market before Novo’s first-quarter results<\/p>\n

Eli Lilly and Co (NYSE:LLY)<\/a> has won FDA approval for Foundayo, its oral GLP-1 weight-loss drug, with a commercial launch set for April 6.<\/p>\n

The approval, which Citi flagged as a must-read development for Novo Nordisk (NYSE:NVO)<\/a> investors, arrives at one of the most difficult moments in Danish drugs giants recent history and opens a new front in the battle for the obesity market.<\/p>\n

Foundayo, known generically as orforglipron, will be priced at $149 a month for the cash-pay starter dose, matching Novo’s Wegovy pill.<\/p>\n

Patients on commercial insurance will pay a $25 copay, rising to $50 under Medicare Part D. Citi, which covers Novo Nordisk and maintains a Neutral rating on the stock, said the oral GLP-1 race is now fully underway.<\/p>\n

Label differences and global reach<\/p>\n

The two pills are not identical in terms of safety. Foundayo carries a thyroid tumour boxed warning, as does Wegovy, but it also comes with additional drug interaction restrictions that Novo’s product does not. Simvastatin dosing is capped at 20mg at the starter dose, use with strong CYP3A4 inhibitors is limited to a 9mg maximum, and CYP3A4 inducers should be avoided altogether.<\/p>\n

Foundayo does, however, lack the 30-minute post-dose restriction on food, drink and other oral medications that applies to the Wegovy pill, a practical advantage that could influence patient and prescriber preference.<\/p>\n

On global ambitions, Lilly has filed in 40 countries, against a more selective international rollout from Novo. Citi noted that Lilly may launch ahead of the Wegovy pill in a number of markets, resulting in a meaningful commercial headwind for Novo’s international business.<\/p>\n

Morgan Stanley flags a tough first quarter<\/p>\n

The timing of Foundayo’s arrival compounds pressure that Morgan Stanley analysts had already identified ahead of Novo’s first-quarter results.<\/p>\n

In a note published on Wednesday, the American investment bank, which holds an ‘equal-weight’ rating and a $40 price target on the ADR, said Q1 is likely to be the hardest quarter of 2026 for Novo.<\/p>\n

It pointed to a negative price and mix effect on US Wegovy, driven by lower injectable cash-pay prices, a higher proportion of cash-pay patients and a low average price for the pill, where most patients remain on starter doses.<\/p>\n

Currency headwinds are expected to take 9% off first-quarter sales at the Morgan Stanley estimate level.<\/p>\n

Morgan Stanley forecasts Wegovy pill sales of $2 billion\u00a0for the full year and expects injectable script volumes to recover to 330,000 a week in the second half of 2026 as Medicare Part D coverage opens up. The bank stands fractionally above the top end of Novo’s own guidance, projecting a sales decline of 4% in constant currency terms.<\/p>\n","protected":false},"excerpt":{"rendered":"GLP-1 wars: Lilly’s FDA-approved oral weight-loss pill puts Novo Nordisk’s Wegovy franchise under fresh pressure Proactive uses images…\n","protected":false},"author":2,"featured_media":54395,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1893,3085,272],"class_list":["post-54394","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-citi","tag-morgan-stanley","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116337621420738885","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=54394"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54394\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/54395"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=54394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=54394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=54394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}